Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 1999

View Archived Issues

Novel echinocandin B tested in neutropenic rabbit model of disseminated candidiasis

In vivo antiangiogenic activity described for FMPA

Company Profile: AtheroGenics

Aurora Biosciences announces two new collaborations with Merck

COX-2 inhibitors: pros and cons debated in current literature

Teva signs letter of intent to acquire Novopharm

Very promising clinical trial results achieved with leukemia treatment

Hollis-Eden reports preliminary results from phase I/II HIV trial in South Africa

Factor Xa inhibitors described by Merck

New series of uroselective alpha1-adrenoceptor antagonists in development at Abbott

Cannabinoids with selectivity for CB2 receptor designed at U.S. university

GABA-A receptor agonists/inverse agonists disclosed by Dainippon

Novel hematinic agent SB-251353 has synergistic effects with G-CSF in preclinical models

Neuroprotective profile of new AMPA/kainate antagonist presented at Neuroscience meeting

Hughes Institute's COBRA compounds target a novel tubulin binding site

Pyridazinone cell adhesion inhibitors investigated as promising antiinflammatory agents

MR-2917: centrally acting muscle relaxant with reduced side effects

Optical resolution of TAN-67; analgesic activity resides in (-)-enantiomer

Gilead terminates U.S. development of adefovir dipivoxil for HIV

News flash: highlights from the AstraZeneca pipeline review

Neuroprotective use-dependent blocker of voltage-dependent Na+ channels, BIII-890-CL

Calpain inhibitor BDA-410 exerts neuroprotective effects in preclinical models

News from ASH: Hemolink performs extremely well in phase II trial in CABG patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...